Skip to main
VCYT
VCYT logo

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 20%
Hold 20%
Sell 10%
Strong Sell 0%

Bulls say

Veracyte Inc. has demonstrated a strong upward trajectory in profitability metrics, with management raising its adjusted EBITDA margin guidance for 2025 to approximately 22.5%, an increase of 190 basis points from the 2024 forecast. The company has also reported a significant year-over-year improvement in its non-GAAP operating margin, which increased by 590 basis points to reach 19.3%. Additionally, the adjusted EBITDA margin for the prior year stood at 21.6%, reflecting an impressive year-over-year growth of 670 basis points, indicating robust operational efficiency and financial health.

Bears say

Veracyte Inc faces significant challenges, as there are critical concerns regarding weaker-than-expected sales from its key diagnostic tests, Decipher and Afirma, which are critical to its revenue streams. Additionally, the company is reporting deteriorating financial metrics, with the estimated revenue per test declining by approximately 4% year-over-year, indicating potential difficulties in maintaining profitability. Furthermore, concerns about operating margins and free cash flow positions may further exacerbate the company's financial outlook and overall market stability.

Veracyte (VCYT) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 10 analysts, Veracyte (VCYT) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.